258 related articles for article (PubMed ID: 18094032)
1. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
Krämer S; Wang-Rosenke Y; Scholl V; Binder E; Loof T; Khadzhynov D; Kawachi H; Shimizu F; Diekmann F; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
[TBL] [Abstract][Full Text] [Related]
2. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
Martini S; Krämer S; Loof T; Wang-Rosenke Y; Daig U; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1761-70. PubMed ID: 17356129
[TBL] [Abstract][Full Text] [Related]
3. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.
Krämer S; Binder E; Loof T; Wang-Rosenke Y; Martini S; Khadzhynov D; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2009 Jul; 297(1):F218-27. PubMed ID: 19439518
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Krämer S; Kron S; Wang-Rosenke Y; Loof T; Khadzhynov D; Morgera S; Kawachi H; Shimizu F; Martini S; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F801-11. PubMed ID: 18216152
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat.
Wang-Rosenke Y; Khadzhynov D; Loof T; Mika A; Kawachi H; Neumayer HH; Peters H
BMC Nephrol; 2013 Oct; 14():223. PubMed ID: 24119229
[TBL] [Abstract][Full Text] [Related]
7. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2006 Jan; 290(1):F167-76. PubMed ID: 16048904
[TBL] [Abstract][Full Text] [Related]
8. Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Villa L; Boor P; Konieczny A; Kunter U; van Roeyen CR; Denecke B; Gan L; Neusser MA; Cohen CD; ; Eitner F; Scholl T; Ostendorf T; Floege J
J Pathol; 2013 Apr; 229(5):672-84. PubMed ID: 23192593
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
10. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
Peters H; Martini S; Wang Y; Shimizu F; Kawachi H; Krämer S; Neumayer HH
Kidney Int; 2004 Oct; 66(4):1434-43. PubMed ID: 15458436
[TBL] [Abstract][Full Text] [Related]
11. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
[TBL] [Abstract][Full Text] [Related]
13. Uninephrectomy induces progressive glomerulosclerosis and apoptosis in anti-Thy1 glomerulonephritis.
Sakai N; Iseki K; Suzuki S; Mori T; Hagino S; Zhang Y; Yokoya S; Kawasaki Y; Suzuki J; Isome M; Wada I; Homma Y; Suzuki H
Pathol Int; 2005 Jan; 55(1):19-26. PubMed ID: 15660699
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin attenuates the severity of murine adriamycin nephropathy.
Lui SL; Tsang R; Chan KW; Zhang F; Tam S; Yung S; Chan TM
Am J Nephrol; 2009; 29(4):342-52. PubMed ID: 18948688
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
17. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
Bonegio RG; Fuhro R; Wang Z; Valeri CR; Andry C; Salant DJ; Lieberthal W
J Am Soc Nephrol; 2005 Jul; 16(7):2063-72. PubMed ID: 15917339
[TBL] [Abstract][Full Text] [Related]
19. Moderate alcohol intake has no impact on acute and chronic progressive anti-thy1 glomerulonephritis.
Peters H; Martini S; Woydt R; Rückert M; Shimizu F; Kawachi H; Liefeldt L; Krämer S; Neumayer HH
Am J Physiol Renal Physiol; 2003 May; 284(5):F1105-14. PubMed ID: 12676738
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin slows IgA nephropathy progression in the rat.
Tian J; Wang Y; Zhou X; Li Y; Wang C; Li J; Li R
Am J Nephrol; 2014; 39(3):218-29. PubMed ID: 24603476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
